JP2017525704A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525704A5
JP2017525704A5 JP2017509739A JP2017509739A JP2017525704A5 JP 2017525704 A5 JP2017525704 A5 JP 2017525704A5 JP 2017509739 A JP2017509739 A JP 2017509739A JP 2017509739 A JP2017509739 A JP 2017509739A JP 2017525704 A5 JP2017525704 A5 JP 2017525704A5
Authority
JP
Japan
Prior art keywords
seq
chain
amino acid
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017509739A
Other languages
English (en)
Japanese (ja)
Other versions
JP6742986B2 (ja
JP2017525704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/046173 external-priority patent/WO2016029061A1/en
Publication of JP2017525704A publication Critical patent/JP2017525704A/ja
Publication of JP2017525704A5 publication Critical patent/JP2017525704A5/ja
Application granted granted Critical
Publication of JP6742986B2 publication Critical patent/JP6742986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017509739A 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤 Active JP6742986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462039809P 2014-08-20 2014-08-20
US62/039,809 2014-08-20
PCT/US2015/046173 WO2016029061A1 (en) 2014-08-20 2015-08-20 Lyophilized formulations for factor xa antidote

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019165981A Division JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤

Publications (3)

Publication Number Publication Date
JP2017525704A JP2017525704A (ja) 2017-09-07
JP2017525704A5 true JP2017525704A5 (2) 2018-09-13
JP6742986B2 JP6742986B2 (ja) 2020-08-19

Family

ID=55351266

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017509739A Active JP6742986B2 (ja) 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Country Status (14)

Country Link
US (6) US20160237420A1 (2)
EP (2) EP3750556A1 (2)
JP (4) JP6742986B2 (2)
KR (3) KR102867491B1 (2)
CN (2) CN113171447B (2)
AU (3) AU2015305413B2 (2)
CA (1) CA2961739C (2)
DK (1) DK3182993T3 (2)
EA (2) EA036091B1 (2)
ES (1) ES2814157T3 (2)
IL (2) IL250413B (2)
SG (1) SG11201701247RA (2)
WO (1) WO2016029061A1 (2)
ZA (1) ZA201701764B (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3121271B1 (en) * 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
EP3750556A1 (en) * 2014-08-20 2020-12-16 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
WO2017147522A1 (en) * 2016-02-24 2017-08-31 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
WO2018213151A1 (en) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Pharmaceutical formulation comprising incretin-insulin conjugates
CN112512480B (zh) * 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
CN110760479A (zh) * 2019-05-17 2020-02-07 上海交通大学医学院附属瑞金医院 靶向血小板表达的凝血因子Xa及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504769A (ja) 1992-12-15 1996-05-21 コルバス・インターナショナル、インコーポレイテッド 因子Ｘａの新規インヒビター
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6586584B2 (en) * 2001-01-29 2003-07-01 Becton, Dickinson And Company Sequences and methods for detection of Hepatitis C virus
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
PE20070717A1 (es) 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
WO2010026186A1 (en) 2008-09-03 2010-03-11 Octapharma Ag New protecting compositions for recombinantly produced factor viii
MX2011004907A (es) * 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
EP3121271B1 (en) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
CA2796729C (en) * 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
GB201310946D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Antidote
EP3750556A1 (en) * 2014-08-20 2020-12-16 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote

Similar Documents

Publication Publication Date Title
JP2017525704A5 (2)
JP2017043632A5 (2)
RU2011151286A (ru) Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
EA201892446A1 (ru) Фармацевтическая композиция
JP2015231997A5 (2)
JP5960990B2 (ja) 組み換え技術によって製造された第ｖｉｉｉ因子のための新規な保護組成物
JP2009540001A5 (2)
JP2013503110A5 (2)
EA200870264A1 (ru) Композиция антител
JP2012515221A5 (2)
JP2013079270A5 (2)
JP2016520075A5 (2)
JP2014514275A5 (2)
TWI285106B (en) Stable pharmaceutical composition containing factor VIII
JP6516829B2 (ja) 第ｖｉｉｉ因子製剤
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2017510585A5 (2)
JP2026010692A (ja) 第ｘａ因子誘導体の調製
JP2002249441A (ja) 血液凝固第ｖｉｉ因子を活性化するプロテアーゼ又はそのプロ酵素の安定化された液体製剤
RU2012122793A (ru) Композиция, способ и набор для альфа-1 ингибитора протеазы
MX349837B (es) Composicion de transglutaminasa seca.
JP5069661B2 (ja) ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
RU2021107534A (ru) Составы, содержащие антитела
CA2956412C (en) Factor viii formulation
RU2018126355A (ru) Фармацевтическая композиция, содержащая антитело к рецептору tslp человека